Biological functions and therapeutic potential of SHCBP1 in human cancer

Lin, Ye; Cai, Hong

doi:10.1016/j.biopha.2023.114362

Cited by 4 publications

(3 citation statements)

References 87 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…SHCBP1 have been demonstrated to be high expressed in different types of cancer and promote cell proliferation, migration, and cell cycle progression (11). Wang et al (22) analyzed the TCGA and GTEx databases and found that SHCBP1 was upregulated in ovarian serous cystadenocarcinoma.…”

Section: Discussionmentioning

confidence: 99%

“…Recent studies indicate SHCBP1 plays critical roles in the progression of different types of cancer. SHCBP1 is overexpressed in bladder (5), pancreatic(6), gastric (7), liver(8), breast (9), lung cancer (10) and other tumors (11). The upregulation of SHCBP1 is associated with poorer prognosis of patients with glioma (12), breast cancer (9), papillary thyroid carcinoma (13) and head and neck squamous cell carcinoma (14).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

SHCBP1 Promotes Cisplatin Resistance of Ovarian Cancer Through AKT/mTOR/Autophagy Pathway

Qi,

Ma,

Teng

et al. 2024

Preprint

View full text Add to dashboard Cite

Ovarian cancercaused the highest cancer-related mortality among female reproductive system malignancies. Platinum-based chemotherapy is still the footstone of the chemotherapy for ovarian cancer. However, the molecular mechanisms underlying cisplatin insensitivity and resistance remain unclear. SHC SH2 domain-binding protein 1 (SHCBP1) plays critical roles in the progression and drug resistance of different types of cancer. However, the biological function of SHCBP1 in ovarian cancer progression and cisplatin resistance remains obscure. In this study, we found that SHCBP1 was up-regulated in ovarian cancer and the up-regulated SHCBP1 has growth-promoting effect on ovarian cancer cells. Furthermore, SHCBP1silencing sensitize ovarian cancer cells to CDDP. Mechanism analysis revealed that SHCBP1 activated the Akt/mTOR pathway and further inhibited autophagy in ovarian cancer cells. Meanwhile, Autophagy inhibitors combined with SHCBP1 knockdown enhances CDDP sensitivity. In addition, SHCBP1 inhibition restrained the proliferation of tumorsand increased the cisplatin sensitivity in vivo. These findings suggested that up-regulated SHCBP1 promoted the proliferation and CDDP resistance of ovarian cancer.The combination of SHCBP1 inhibition and cisplatin treatment might lead to substantial progress in ovarian cancer targeted therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

SHCBP1 Promotes Cisplatin Resistance of Ovarian Cancer Through AKT/mTOR/Autophagy Pathway

Qi,

Ma,

Teng

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

“…[17][18][19] SHC binding and spindle-associated 1 (SHCBP1) is a protein that specifically binds to the SH2 domain of Src homology-collagen, and its abnormal expression has been linked to cancer in various systems. [20] SLITRK3, a homologous transmembrane protein, has been implicated in the risk rating and prognosis of gastrointestinal stromal tumors. [21] Moreover, increased expression of SLITRK3 in LUSC has been linked to unfavorable clinical outcomes, potentially attributable to its function in facilitating SLITRK3-mediated activation of NTRK3, thereby promoting a cancer stem cell phenotype.…”

Section: Discussionmentioning

confidence: 99%

A prognostic signature associated with cell senescence predicts survival outcomes and strongly associates with immunotherapy and chemotherapy response in breast cancer

Pan

et al. 2023

Medicine

View full text Add to dashboard Cite

The objective of this study is to assess the predictive potency of cell senescence-related genes (CSRGs) in breast cancer (BC) and establish a risk signature. Trascriptome data of CSRGs were obtained from the TCGA and GEO databases. Consensus clustering was used to generate CSRGs-based molecular clusters for BC patients. A CSRGs-derived risk signature was built using multiple Cox regression analyses of differentially expressed genes (DEGs) between clusters. The prognosis, immune infiltration, chemotherapy and immunotherapy response between different risk groups were analyzed and compared. Two molecular clusters of BC patients were generated on the basis of 79 differentially expressed CSRGs, which showed distinct prognosis and immune infiltration. A total of 1403 DEGs between the CSRGs-derived clusters were found, and 10 of them were independent prognostic genes that used to construct a risk signature. The results demonstrated that patients with older age and advanced stage presented with a higher risk scores. In addition, the risk signature was found to be associated with outcomes, immune infiltration, chemotherapy and immunotherapy response. Patients in the low-risk group showed a favorable prognosis and higher immunotherapy response than those in the high-risk group. Finally, we developed a highly stable nomogram that incorporates risk signature, chemotherapy, radiotherapy, and stage variables, enabling accurate prediction of the overall survival (OS) of individual patients. To conclude, the signature derived from CSRGs holds great promise as a biomarker for prognostic assessment of BC and may serve as a valuable tool in guiding immunotherapy.Abbreviations: BC = breast cancer, CCL19 = C-C motif chemokine ligand 19, CSRGs = cell senescence-related genes, DCs = dendritic cells, DEGs = differentially expressed genes, GO = gene ontology, IPS = immunophenoscore, KEGG = Kyoto encyclopedia of genes and genomes, NET = neutrophil extracellular trap, OS = overall survival, SHCBP1 = SHC binding and spindle-associated 1, TIDE = tumor immune dysfunction and exclusion.

show abstract